Biokinetica S.A.

Jozefow 15 trials 5 recruiting

15 Registered trials

5 Currently recruiting

Organisation

Biokinetica S.A.

Location

Jozefow, Poland

Identifier

ORG-100044263

Address

Ul. Nadwislanska 37, 05-420, Poland

Departments

Biokinetica
Cardiology
CWBK
n.a.
N/A
NA
ND
Oncology
Przychodnia Józefów

Clinical trials at this site (15)

Search interface

A study to investigate the pharmacokinetics and safety of KM04 compared to US-Gonal-f RFF Redi-ject and EU-Gonal-f in healthy adult female v… Not authorised

2025-523368-19-00 Functional female infertility 2
A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in … Pending

2024-511220-14-00 Mild Asthma 3
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy o… Pending

2025-525113-22-00 Rheumatoid Arthritis 1
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease Recruiting

2025-521462-96-00 Sjogren's Disease 3 2025-08-05
A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) Recruiting

2024-519114-31-00 Treatment-Refractory Rheumatoid Arthritis 3 2025-05-15
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability… Recruiting

2024-516197-30-00 Idiopathic or diabetic gastroparesis 3 2025-07-16
A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting

2024-517147-31-00 Tumours, Gynecological 9 2025-05-23
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi… Recruiting

2024-514010-12-00 Advanced Malignancies 1 2020-12-03
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300… Ended

2023-506541-39-00 Small Cell Lung Cancer 1 2018-08-03
Comparison of Prefilled syringe and Autoinjector presentations of FYB202 Ended

2025-522422-13-00 Chronic inflammatory diseases 2 2025-11-15
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination… Ended

2024-511744-27-00 Solid tumors, Non-Small Cell Lung Cancer, Cervical Canc 1 2022-06-27
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24